Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7763505 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: SAD, MAD, and Food Effect in Healthy Participants | EXPERIMENTAL | Healthy participants will receive RO7763505 or matching placebo. |
| Part 2: In Stable CAD Participants | EXPERIMENTAL | Participants with stable CAD will receive RO7763505 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| RO7763505 | DRUG | Participants will receive RO7763505 as per the schedule described in the protocol. |
| Placebo | DRUG | Participants will receive matching placebo as per the schedule described in the protocol. |
Inclusion Criteria: Part 1: * Healthy biologically male and female participants of nonchildbearing potential or childbearing potential with no clinically relevant findings on physical examination at screening or baseline (assessed either on Day -2 or Day -1), including detailed medical and surgica...
RO7763505 is an investigational small molecule being studied for stable coronary artery disease. It is in Phase 1 clinical development by Roche Holding AG (RHHBY). The drug is being evaluated in a clinical trial that includes both healthy volunteers and people with stable heart disease.
RO7763505 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is currently in Phase 1 clinical development for stable coronary artery disease. Roche is conducting a randomized, double-blind, controlled study to evaluate the drug.
RO7763505 is in Phase 1 clinical development. It is an investigational drug being studied for stable coronary artery disease and has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants.
RO7763505 is being studied in a Phase 1 clinical trial with the identifier NCT07495813. This randomized, double-blind, controlled study is evaluating how the drug works and how safe it is when given to healthy people and people with stable heart disease. The trial is recruiting in the Netherlands and aims to enroll 196 participants.
Yes, RO7763505 is being studied in healthy volunteers as part of its Phase 1 clinical trial. The study, NCT07495813, includes both healthy volunteers and people with stable coronary artery disease. The trial is recruiting participants aged 18 years and older in the Netherlands.